Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy.
about
Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in TumorGefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate.Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worseEfficacy of tyrosine kinase inhibitors in non-small-cell lung cancer patients undergoing dose reduction and those with a low body surface areaBayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.Successful treatment of EGFR-mutated non-small cell lung cancer with reduced-dose gefitinib: A case report.Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in miceErlotinib in non-small cell lung cancer: a review.Novel therapeutics in adult malignant brain gliomas.Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer.Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefitinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancerEpidermal growth factor receptor inhibition and non-small cell lung cancer.Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: Preliminary results of a phase II study.Efficacy of first-line erlotinib in non-small cell lung cancer patients undergoing dose reduction and those with a low body surface area: A population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research GroupGefitinib for the treatment of non-small-cell lung cancer.Daily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendations from a multinational expert panel.Algorithm for dermocosmetic use in the management of cutaneous side-effects associated with targeted therapy in oncology.EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.The evolution of phase I trials in cancer medicine: a critical review of the last decade.Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors.Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan.Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteersMatuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers.Determination of a radotinib dosage regimen based on dose-response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia.Effect of Sustained Elevated Gastric pH Levels on Gefitinib Exposure.
P2860
Q27342948-068782D2-9B11-4F5B-B5B8-C8B49B9569F5Q33367963-F3AFC990-FBF5-4D93-889D-EF7D99BAE636Q33658203-BC7A7EFC-40B3-4A51-B92C-2A3CEFD29689Q33733770-30C82029-7A70-479C-8DC5-96BA6D41588BQ33827699-4B8C010D-B687-4813-86B2-440E7F86C560Q35803490-E5CE0E8F-A5B0-48EE-8537-F2B0567CFBCFQ36153295-036E711A-2125-43C3-A149-9F14B4023908Q36161290-52BF99BE-68EC-4E59-9252-A941CACAC1EBQ36187046-4FF54F7C-B072-43AE-9B8A-452530BEEAFDQ36302860-73BD107C-FBEB-49CE-A8F2-5EB4EF986595Q36477753-680DF6F2-6533-4846-AB18-D40C77B640B6Q36504349-01221900-262D-49F3-8441-6BD77055DE6BQ36546095-9A7CFB84-1E53-40F5-AC25-7F520D65A10CQ36640486-AE9DDC10-7CDB-4B4C-89F1-ECBA1EF5992CQ37357287-2712E391-8396-4F8E-A64F-8388BC82AFB9Q37390753-AF0A66FF-29A7-4937-8936-91EA49771FCAQ37442683-F99FAC73-3EFC-43FD-A102-D35AE2078270Q37709182-A60D7488-CD1E-4D87-9E84-5DB7E3F57350Q37873453-483CE576-6566-4153-9DF5-70D6D0503044Q37953478-DD3649B7-CA40-4819-82EB-02F65B47D1B4Q37987802-8F79D44B-E988-44CE-8545-915B3308FCABQ40975815-910F2880-0040-4F1D-84B1-2DB5A4313E3EQ42106492-BA02A28A-1A94-48FA-9B38-58894562594EQ42661688-51A381C1-1BB6-4C6B-997C-089B2ADB733FQ47387077-96D85F1A-C5C1-4B54-974A-B5601B0C10F0Q52631989-11F1407B-5E24-491F-A0C0-B999362D3B1BQ53519220-880A29A4-84BA-46A0-BA1B-24CFC242149D
P2860
Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Development of the novel biolo ...... um dose for clinical efficacy.
@ast
Development of the novel biolo ...... um dose for clinical efficacy.
@en
type
label
Development of the novel biolo ...... um dose for clinical efficacy.
@ast
Development of the novel biolo ...... um dose for clinical efficacy.
@en
prefLabel
Development of the novel biolo ...... um dose for clinical efficacy.
@ast
Development of the novel biolo ...... um dose for clinical efficacy.
@en
P2093
P1476
Development of the novel biolo ...... um dose for clinical efficacy.
@en
P2093
Helen Swaisland
Michael Wolf
Steven Averbuch
P304
P356
10.1158/1078-0432.CCR-04-0058
P407
P577
2004-07-01T00:00:00Z